piperidines has been researched along with gepirone* in 3 studies
3 other study(ies) available for piperidines and gepirone
Article | Year |
---|---|
Behavioural evidence for a functional interaction between central 5-HT2 and 5-HT1A receptors.
1. The possibility of 5-HT2 receptor modulation of central 5-HT1A receptor function has been examined using the 5-hydroxytryptamine (5-HT) behavioural syndrome induced by 5-HT1A receptor active drugs in rats. 2. The 5-HT2/5-HTIC antagonist ritanserin (0.1-2 mg kg-1) increased the 5-HT behavioural syndrome induced by submaximally effective doses of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), 5-methoxy-N,N-dimethyltryptamine (5-MeODMT) and gepirone. 3. Pretreatment with the 5-HT2/5-HT1C antagonist ICI 170,809 (0.25-5 mg kg-1) also enhanced the behavioural syndrome induced by 8-OH-DPAT or 5-MeODMT. 4. The 5-HT2/alpha 1-adrenoceptor antagonist ketanserin in a low dose (0.25 mg kg-1) significantly increased the 5-HT behavioural syndrome induced by 8-OH-DPAT or 5-MeODMT, while in a higher dose (2.5 mg kg-1) this drug decreased the response. Experiments with prazosin indicate that the higher dose of ketanserin might reduce the 5-HT behavioural syndrome through blockade of alpha 1-adrenoceptors. 5. Ritanserin and ICI 170,809 had no effect on apomorphine-induced stereotypy or hyperactivity, indicating that these drugs do not produce non-specific behavioural activation. 6. Ritanserin and ICI 170,809 inhibited quipazine-induced wet dog shakes at doses similar to those enhancing the 5-HT behavioural syndrome. 7. We suggest that ritanserin, ICI 170,809 and ketanserin enhance 5-HT1A agonist-induced behaviour through blockade of an inhibitory 5-HT2 receptor regulating or coupled to 5-HT1A receptor-mediated function. Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Apomorphine; Behavior, Animal; Central Nervous System; Dose-Response Relationship, Drug; Haloperidol; Ketanserin; Male; Methoxydimethyltryptamines; Piperidines; Prazosin; Pyrimidines; Quinolines; Rats; Rats, Inbred Strains; Receptors, Serotonin; Ritanserin; Serotonin; Stereotyped Behavior; Tetrahydronaphthalenes | 1990 |
Effect of serotonergic drugs on negative contrast in consummatory behavior.
The effect of acute and chronic administration of the 5-HT1A agonist buspirone on successive negative contrast was investigated in Experiments 1-6. Contrast in consummatory behavior was induced by shifting rats from a 32% to a 4% sucrose solution. Experiments 1-5 showed that buspirone (0.125, 0.25, 0.5, 1.0, 2.0, 15.0 mg/kg) was ineffective in alleviating contrast or in facilitating recovery from contrast. The 15 mg/kg dose substantially decreased consummatory responding. Experiment 6 showed that the chronic (24 days) administration of buspirone (0.5, 2.0 mg/kg) also did not alleviate contrast. The chronic, but not the acute administration of the 2.0 mg/kg dose decreased consummatory behavior. In Experiment 7 the 5-HT1A agonist gepirone (2.5, 5.0 and 10.0 mg/kg) was also found to be ineffective in reducing contrast but, at the higher doses, decreased overall sucrose intake. Experiments 8 and 9 found that the 5-HT2 antagonists ketanserin (2.0 and 8.0 mg/kg) and ritanserin (0.63 and 2.5 mg/kg) also did not alleviate contrast. Midazolam (1.0 mg/kg), included as a positive control, eliminated contrast. These data suggest that serotonergic mechanisms are not involved in negative contrast. Topics: Animals; Buspirone; Chlordiazepoxide; Cyproheptadine; Dose-Response Relationship, Drug; Ethanol; Feeding Behavior; Fenclonine; Injections, Intraperitoneal; Injections, Subcutaneous; Ketanserin; Male; Midazolam; Nucleus Accumbens; Piperidines; Pyrimidines; Rats; Rats, Inbred Strains; Ritanserin; Serotonin; Serotonin Antagonists | 1990 |
Monoaminergic involvement in the pharmacological actions of buspirone.
Buspirone, MJ-13805 and MJ-13653 did not produce a '5-hydroxytryptamine (5-HT) syndrome' in rats at doses up to 20 mg kg-1. These drugs were very weak 5-HT uptake blockers (IC50 much greater than 10 microM) compared to drugs such as chlorimipramine. These drugs did not inhibit either monoamine oxidase (MAO)-A or MAO-B. The Ki values for these agents as inhibitors of [3H]-5-HT and [3H]-ketanserin binding to rat frontal cortex or hippocampal membranes were in the microM range, well above the brain concentrations achieved after an oral dose of 25 mg kg-1. Parenterally administered buspirone blocked apomorphine-induced stereotypy, inhibited the 5-HT syndrome elicited by 5-methoxy-N,N-dimethyltryptamine, and delayed the onset of p-chloroamphetamine induced behaviours. Topics: Animals; Apomorphine; Behavior, Animal; Brain; Buspirone; Dopamine; Ketanserin; Male; Methoxydimethyltryptamines; Monoamine Oxidase; p-Chloroamphetamine; Piperazines; Piperidines; Psychotropic Drugs; Pyrimidines; Rats; Serotonin | 1985 |